Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment por Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, Ouyang M, Zhou CZ

Ligazón do recurso